行情

FOMX

FOMX

Foamix
NASDAQ

实时行情|Nasdaq Last Sale

2.990
-0.250
-7.72%
已退市 18:50 03/06 EST
开盘
3.180
昨收
2.990
最高
3.440
最低
2.900
成交量
193.09万
成交额
--
52周最高
4.840
52周最低
1.970
市值
1.84亿
市盈率(TTM)
-2.3018
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测FOMX价格均价为13.60,最高价位16.00,最低价为11.00。

EPS

FOMX 新闻

更多
  • 吉利德董事长:已向超千人提供瑞德西韦 几周内将有初步数据
  • 澎湃新闻 · 1小时前
  • 大众CEO迪斯:每周损失20亿欧元 除中国市场外无收入
  • 21世纪经济报道 · 1小时前
  • 美国医用防护物资短缺 特朗普:波音、福特也要造呼吸机!
  • 环球网 · 2小时前
  • 朝“虑”夕改 特朗普称没必要对纽约等三州进行隔离
  • 央视 · 2小时前

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

FOMX 简况

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
展开

微牛提供Foamix Pharmaceuticals Ltd(NASDAQ-FOMX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的FOMX股票新闻,以帮助您做出投资决策。